Literature DB >> 7194441

Complications of chronic levodopa therapy: long-term efficacy of drug holiday.

W C Koller, W J Weiner, S Perlik, P A Nausieda, C G Goetz, H L Klawans.   

Abstract

Chronic use of levodopa may be complicated by dyskinesias, on-off effect, or hallucinosis. Transient levodopa withdrawal (drug holiday) may increase motor responsiveness and decrease levodopa-induced side effects, and the improved state may persist for as long as 9 months. After 1 year, parkinsonian signs approached pre-holiday levels, and two of the patients required a second drug holiday; side effects began to reappear 9 to 12 months after the holiday. Four of six patients with psychiatric complications remained free of hallucinations for the entire year.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7194441     DOI: 10.1212/wnl.31.4.473

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  8 in total

Review 1.  An update expert opinion on management and research strategies in Parkinson's disease psychosis.

Authors:  Jennifer G Goldman; Christina L Vaughan; Christopher G Goetz
Journal:  Expert Opin Pharmacother       Date:  2011-06-02       Impact factor: 3.889

2.  Complications of therapy in Parkinson's disease.

Authors:  O S Kofman
Journal:  Can Fam Physician       Date:  1983-01       Impact factor: 3.275

Review 3.  Levodopa in Parkinson's disease: neurotoxicity issue laid to rest?

Authors:  M G Murer; R Raisman-Vozari; O Gershanik
Journal:  Drug Saf       Date:  1999-11       Impact factor: 5.606

Review 4.  Anti-parkinsonian drugs today.

Authors:  N P Quinn
Journal:  Drugs       Date:  1984-09       Impact factor: 9.546

5.  The effects of acute levodopa withdrawal on motor performance and dopaminergic receptor sensitivity in patients with Parkinson's disease.

Authors:  N Turjanski; W Fernandez; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-07       Impact factor: 10.154

Review 6.  Visual hallucinations in the elderly associated with the use of levodopa.

Authors:  A K Banerjee; P G Falkai; M Savidge
Journal:  Postgrad Med J       Date:  1989-06       Impact factor: 2.401

7.  Genetic silencing of striatal CaV1.3 prevents and ameliorates levodopa dyskinesia.

Authors:  Kathy Steece-Collier; Jennifer A Stancati; Nicholas J Collier; Ivette M Sandoval; Natosha M Mercado; Caryl E Sortwell; Timothy J Collier; Fredric P Manfredsson
Journal:  Mov Disord       Date:  2019-04-19       Impact factor: 10.338

8.  Schizotypy in Parkinson's disease predicts dopamine-associated psychosis.

Authors:  Carina R Oehrn; Jana Schönenkorb; Lars Timmermann; Igor Nenadić; Immo Weber; Phillip Grant
Journal:  Sci Rep       Date:  2021-01-12       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.